SCHEMBL1877367

SCHEMBL1877367

Cc1ccc(-c2noc(NC(=O)Cc3ccccc3Cl)c2-c2ccncn2)cc1C

nearest known ligand 0.82

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.82
MAPK9 P45984 1/20 0.60
MAPK10 P53779 1/20 0.60
MAPK11 Q15759 1/20 0.60
TP53 P04637 1/20 0.40
SENP2 Q9HC62 1/20 0.40
SENP1 Q9P0U3 1/20 0.40
RORA P35398 1/20 0.39
NR2E1 Q9Y466 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
THRB P10828 1/20 0.39
KCNJ6 P48051 1/20 0.39
KCNJ5 P48544 1/20 0.39
KCNJ3 P48549 1/20 0.39
ANO1 Q5XXA6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1871375 0.96 MAPK14 (0.82) MAPK14MAPK9MAPK10MAPK11SENP2
SCHEMBL1881005 0.93 MAPK14 (0.86) MAPK14MAPK9MAPK10MAPK11RORA
SCHEMBL1872250 0.93 MAPK14 (0.78) MAPK14MAPK9MAPK10MAPK11RORA
SCHEMBL1874662 0.92 MAPK14 (0.75) MAPK14MAPK9MAPK10MAPK11
SCHEMBL1886765 0.91 MAPK14 (0.83) MAPK14MAPK9MAPK10MAPK11KCNJ5
SCHEMBL1874026 0.90 MAPK14 (0.81) MAPK14MAPK9MAPK10MAPK11RORA
SCHEMBL1877324 0.90 MAPK14 (1.00) MAPK14MAPK9MAPK10MAPK11RORA
SCHEMBL1882557 0.90 MAPK14 (0.82) MAPK14MAPK9MAPK10MAPK11KCNJ5
SCHEMBL1875780 0.90 MAPK14 (0.87) MAPK14MAPK9MAPK10MAPK11RORA
SCHEMBL4343967 0.90 MAPK14 (0.66) MAPK14MAPK9MAPK10MAPK11RORA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1832584-B1 PYRIMIDINYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-12-21 EP disclosed
US-7939536-B2 5-[(2-chlorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole; p 38MAP kinase inhibitor; tumor necrosis factor, interleukin, or cyclooxygenase-II related diseases; antiinflammatory, anticarcinogenic, antidiabetic agent ASKA PHARMACEUTICAL CO., LTD. (JP) 2011-05-10 US disclosed
US-20080114003-A1 Pyrimidinylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-15 US disclosed
EP-1832584-A1 PYRIMIDINYLISOXAZOL DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114003-A1 Pyrimidinylisoxazole Derivatives MAPK3, MAPK7, MAP3K7 MAPK14 29/4885MAPK9 20/4885MAPK10 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.